SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03874741
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT03821363
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: recombinant anti-EGFR monoclonal antibody
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03817567
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital., Zhengzhou, Henan, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Human Coagulation FVIII
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT03815318
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03808701
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
- Conditions
- Non-squamous Cell Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT03792074
Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03713372
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03692520
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer
- Conditions
- Triple Negative Breast Neoplasms
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03692689
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT03405272
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China